Chronic Drug-Induced Hepatotoxicity: Clinical Aspects

  • Martin Black


It is a special privilege to contribute a discussion of one aspect of drug hepatotoxicity that is well recognized as having been a major interest of Dr. Zimmerman for much of his professional life. Dr. Zimmerman suspected, and argued without much early success, in favor of the primacy of biochemical events in mediating certain forms of drug hepatotoxicity at a time when the prevailing wisdom focused on the importance of (largely unsubstantiated) immune mechanisms. While observations over the past decade have generally supported Dr. Zimmerman’s views, the area of chronic drug-induced hepatotoxicity is one in which supporting data for the role of biochemical events in mediating such injury remain elusive.


Primary Biliary Cirrhosis Chronic Active Hepatitis Alcoholic Hepatitis Porphyria Cutanea Tarda Drug Hepatotoxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reynolds TB, Lapin AC, Peters RL, Yamahiro HS: Puzzling jaundice. Probable relationship to laxative ingestion. JAMA 211:86–90, 1970.PubMedCrossRefGoogle Scholar
  2. 2.
    McHardy G, Balart LA: Jaundice and oxyphenisatin. JAMA 211:83–85, 1970.PubMedCrossRefGoogle Scholar
  3. 3.
    Anon: Jaundice from oxyphenisatin acetate. JAMA 211:114, 1970.Google Scholar
  4. 4.
    Simpson BR, Strunin L, Walton B: Evidence for halothane hepatotoxicity is equivocal, in Ingelfmger FJ, Ebert RV, Finland M, Relman AS (eds): Controversy in Internal Medicine, Vol. 11. WB Saunders, Philadelphia, 1974, pp. 580–594.Google Scholar
  5. 5.
    Mallory A, Frank BW, Kern F JS: Oxyphenisatin and chronic active hepatitis. S Eng J Med 285:1266, 1971.Google Scholar
  6. 6.
    Pearson AJG, Grainger JM, Scheuer PJ, Mc Intyre S: Jaundice due to oxyphenisatin. Lancet 1:994–996, 1971.PubMedCrossRefGoogle Scholar
  7. 7.
    Willing RL, Hecker R: Oxyphenisatin and liver damage. Med J Aust 58:1179–1182, 1971.Google Scholar
  8. 8.
    Gjone E. Blomhoff JP, Ritland S, Elgjo K, Husby G: Laxative-induced chronic liver disease. Scand J Gastroenterol 7:395–402, 1971.CrossRefGoogle Scholar
  9. 9.
    Zarday Z, Rosenthal WS, Wolff FW: Severe liver toxicity after methyldopa. NY State J Med 67:1897–1899, 1967.Google Scholar
  10. 10.
    Elkington SG, Schreiber WM, Conn HO: Hepatic injury caused by l-alpha-methyldopa. Circulation 40:589–595, 1967.Google Scholar
  11. 11.
    Goldstein GB, Lam KC, Mistilis SP: Drug-induced chronic active hepatitis. Dig Dis 18:177–184, 1973.CrossRefGoogle Scholar
  12. 12.
    Hoyumpa AM Jr, Connell AM: Methyldopa hepatitis: Report of three cases. Dig Dis 18:213–222, 1973.CrossRefGoogle Scholar
  13. 13.
    Maddrey WC, Boitnott JK: Severe hepatitis from methyldopa. Gastroenterology 68:351–360, 1975.Google Scholar
  14. 14.
    Klemola H, Penttila O, Runeberg L, Tallqvist G: Anicteric liver damage during nitrofurantoin medication. Scand J Gastroenterol 10:501–505, 1975.PubMedGoogle Scholar
  15. 15.
    Back O, Lundgren R, Wiman LG: Nitrofiirantoin-induced pulmonary fibrosis and lupus syndrome. Lancet 1:930, 1974.PubMedCrossRefGoogle Scholar
  16. 16.
    Fagrell B, Strandberg I, Wengle B: A nitrofurantoin-induced disorder simulating chronic active hepatitis. Acta Med Scand 199:237–239, 1976.PubMedCrossRefGoogle Scholar
  17. 17.
    Stromberg A, Wangle B: Chronic active hepatitis induced by nitrofurantoin. Br Med J 3:174–175, 1976.CrossRefGoogle Scholar
  18. 18.
    Black M, Rabin L, Schatz S: Nitrofurantoin-induced chronic active hepatitis. Ann Intern Med 92:62–64, 1980.PubMedGoogle Scholar
  19. 19.
    David RB, Andersen HA, Stickler GB: Nitrofurantoin sensitivity: Report of a child with chronic inflammatory lung disease. Am J Dis Child 116:418–421, 1968.PubMedGoogle Scholar
  20. 20.
    Israel KS, Brashear RE, Sharma HM, et al: Pulmonary fibrosis and nitrofurantoin. Am Rev Respir Dis 108:353–356, 1973.PubMedGoogle Scholar
  21. 21.
    Selroos O, Edgren J: Lupus-like syndrome associated with pulmonary reaction to nitrofurantoin. Acta Med Scand 197:125–129, 1975.PubMedCrossRefGoogle Scholar
  22. 22.
    Horiuchi T, Ohtsubo K, Saito M: Furylfuramide-induced hepatic necrosis in mice and its modification by phenobarbital. Jpn J Exp Med 42:111–121, 1976.Google Scholar
  23. 23.
    Olive PL, McCalla DR: Cytotoxicity and DNA damage to mammalian cells by nitrofurans. Chem Biol Interact 16:223–233, 1977.PubMedCrossRefGoogle Scholar
  24. 24.
    Black M, Zimmerman H, Ishak I, et al: Isoniazid hepatitis in 114 patients. Gastroenterology 69:289–302, 1975.PubMedGoogle Scholar
  25. 25.
    Graham WG, Dundas GR: Isoniazid-related liver disease: Occurrence with portal hypertension, hypoalbuminemia and hypersplenism. JAMA 242:353–354, 1979.PubMedCrossRefGoogle Scholar
  26. 26.
    Black M: Acetaminophen hepatotoxicity. Annu Rev Med 35:577–593, 1984.PubMedCrossRefGoogle Scholar
  27. 27.
    Seeff LB, Cuccherini S A, Zimmerman HJ, et al: Acetaminophen hepatotoxicity in alcoholics: A therapeutic misadventure. Ann Intern Med 104:399–404, 1986.PubMedGoogle Scholar
  28. 28.
    Black M: Hepatotoxic and hepatoprotective potential of H2-receptor antagonists. Am J Med 83(Suppl. 6A): 68–75, 1987.PubMedCrossRefGoogle Scholar
  29. 29.
    Coe RO, Bull FE: Cirrhosis associated with methotrexate treatment of psoriasis. JAMA 206:1515–1520, 1968.PubMedCrossRefGoogle Scholar
  30. 30.
    Dahl MGC, Gregory MM, Scheuer PJ: Liver damage due to methotrexate in patients with psoriasis. Br Med J 1:625–630, 1971.PubMedCrossRefGoogle Scholar
  31. 31.
    Roenigk HH Jr, Maibach HI, Weinstein GP: Methotrexate therapy for psoriasis: guideline revisions. Arch Dermatol 108:35, 1973.PubMedCrossRefGoogle Scholar
  32. 32.
    Weinstein GP, Roenigk H, Maibach HI, et al: Psoriasis-liver-methotrexate interactions. Arch Dermatol 108:36–42, 1973.CrossRefGoogle Scholar
  33. 33.
    Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GP: Methotrexate guidelines—Revised. J Am Acad Dermatol 6:145–155, 1982.PubMedCrossRefGoogle Scholar
  34. 34.
    Itoh S, Yougel T, Kawagoe S: Comparison between non-alcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 82:650–654, 1987.PubMedGoogle Scholar
  35. 35.
    Poucell S, Ireton J, Valencia-Mayoral P, et al: Amiodarone-associated phosphilipidosis and fibrosis of the liver: Light, immunohistochemical, and electron microscopic studies. Gastroenterology 86:926–936, 1984.PubMedGoogle Scholar
  36. 36.
    Simon JB, Manley PN, Brien JF, Armstrong PW: Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 311:167–172, 1984.PubMedCrossRefGoogle Scholar
  37. 37.
    Rigas B, Rosenfeld LE, Barwick KW, et al: Amiodarone hepatotoxicity a clinicopathologic study of five patients. Ann Intern Med 104:348–351, 1986.PubMedGoogle Scholar
  38. 38.
    Holt DW, Tucker GT, Jackson PR, Storey GCA: Amiodarone pharmacokinetics. Am Heart J 106:840–846, 1983.PubMedCrossRefGoogle Scholar
  39. 39.
    Harris L, McKenna WJ, Rowland E, et al: Side effects of long-term amiodarone therapy. Circulation 67:45–51, 1983.PubMedCrossRefGoogle Scholar
  40. 40.
    Mason JW: Amiodarone, S Engl J Med 316:455–466, 1987.CrossRefGoogle Scholar
  41. 41.
    Pessayre D, Bichara M, Feldmann G, et al: Perhexilene maleate-induced cirrhosis. Gastroenterology 76:170–177, 1979.PubMedGoogle Scholar
  42. 42.
    Morgan MY, Reshef R, Shah RR, et al: Impaired oxidation of debrisoquine in patients with perhexilene liver injury. Gut 25:1057–1064, 1984.PubMedCrossRefGoogle Scholar
  43. 43.
    Mahgoub A, Idle JR, Dring LG, et al: Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584–586, 1977.PubMedCrossRefGoogle Scholar
  44. 44.
    Price Evans DA, Mahgoub A, Sloan TP, et al: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17:102–105, 1980.CrossRefGoogle Scholar
  45. 45.
    Distlerath LM, Reilly PEB, Martin MV, et al: Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057–9067, 1985.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1989

Authors and Affiliations

  • Martin Black
    • 1
  1. 1.Liver UnitTemple University School of MedicinePhiladelphiaUSA

Personalised recommendations